Safety And Efficacy Of Adding Intravenous N-Acetyl Cysteine To Parenteral L-Alanyl L-Glutamine In Hospitalized Patients Undergoing Colon Surgeries

“Safety And Efficacy Of Adding Intravenous N-Acetyl Cysteine To Parenteral L-Alanyl L-Glutamine In Hospitalized Patients Undergoing Colon Surgeries: A Randomized Controlled Clinical Trial”

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201807118984852

Enrollment

Registered

2018-07-16

Start date

2015-07-30

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System Surgery Anaesthesia

Interventions

N acetylcysteine

dextrose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged between 18 and 80 years. Need for ICU admission after colonic surgery. Requirement of TPN for at least 5 days due to failure of or contraindication for enteral nutrition. Signing a written informed consent

Exclusion criteria

Exclusion criteria: Patients with persistent hemodynamic instability (systolic blood pressure <80 mm Hg). Renal impairment, hepatic insufficiency. Severe or uncontrolled sepsis Persistent metabolic acidosis. Head trauma, heart failure, Any sensitivity to components of L-alanyl L-glutamine (Dipeptiven®, Fresenius Kabi, Germany) or NAC

Design outcomes

Primary

Measure	Time frame
-evaluate the efficacy of NAC through assessing the changes in the serum level of malondialdehyde (MDA) as antioxidant marker ;evaluate changes in the tumor necrosis factor alpha (TNF-a) as anti-inflammatory marker	—

Secondary

Measure	Time frame
safety evaluation by recording any side effect that may appear	—

Countries

Egypt

Contacts

Public Contactdina hussein

pharmacist in elkasr elainy

dina_hussein05@yahoo.com+0201121717315

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026